Cytogen, Inc. (217330.KQ)
KOSDAQ · KRW · Healthcare · Diagnostics & Research
₩2,450 (-2.00%) as of
Key statistics
- Market cap
- 56.66B
- Dividend yield
- 0.00%
- 52-week range
- 2,435.00 – 11,200.00
- Beta
- 0.27
- Revenue (TTM)
- 27.38B
- Profit margin
- -38.52%
- Volume
- 48.93k
About Cytogen, Inc.
Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained with anti-EpCAM, -CD45, and CK antibodies. The company sells its products under the Smart Biopsy brand name. Cytogen, Inc. was founded in 2010 and is headquartered in Seoul, South Korea.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Seoul, South Korea
- Employees
- 42
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.